PLAU and cancer: ECRG2 protein was demonstrated to inhibit the activity of a serine protease known as urokinase-type plasminogen activator (uPA), an enzyme involved in the conversion of inactive plasminogen into active plasmin, which is important in cancer metastasis [5,10].